Functional polymorphisms in the NPAS2 gene are associated with overall survival in transcatheter arterial chemoembolization-treated hepatocellular carcinoma patients

Cancer Science

Volumn 105, Issue 7, 2014, Pages 825-832

  Yuan, Peng ^a   Wang, Shen ^a   Zhou, Feng ^b   Wan, Shaogui ^c   Yang, Yefa ^d   Huang, Xiaojun ^c   Zhang, Zhaohui ^b   Zhu, Yong ^e   Zhang, Hongxin ^a   Xing, Jinliang ^c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatocellular carcinoma; NPAS2; Prognosis; Single nucleotide polymorphism; Transcatheter arterial chemoembolization

Indexed keywords

BIOLOGICAL MARKER; DOXORUBICIN; FLUOROURACIL; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CHEMOEMBOLIZATION; CHINESE; COHORT ANALYSIS; CONFIDENCE INTERVAL; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HAZARD RATIO; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NPAS2 GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SINGLE NUCLEOTIDE POLYMORPHISM;

HEPATOCELLULAR CARCINOMA; NPAS2; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; HAPLOTYPES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 84904284487     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12428     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Chen WQ, Zheng RS, Zhang SW. Liver cancer incidence and mortality in China, 2009. Chin J Cancer 2013; 32: 162-9.
3. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-55.
4. Murata S, Mine T, Ueda T et al. Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma. ScientificWorldJournal 2013; 2013: 479-805.
5. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
6. Kondratov RV, Gorbacheva VY, Antoch MP. The role of mammalian circadian proteins in normal physiology and genotoxic stress responses. Curr Top Dev Biol 2007; 78: 173-216.
7. Lee C, Etchegaray JP, Cagampang FR, Loudon AS, Reppert SM. Posttranslational mechanisms regulate the mammalian circadian clock. Cell 2001; 107: 855-67.
8. DeBruyne JP, Weaver DR, Reppert SM. CLOCK and NPAS2 have overlapping roles in the suprachiasmatic circadian clock. Nat Neurosci 2007; 10: 543-5.
9. Dudley CA, Erbel-Sieler C, Estill SJ et al. Altered patterns of sleep and behavioral adaptability in NPAS2-deficient mice. Science 2003; 301: 379-83.
10. Hoffman AE, Zheng T, Ba Y, Zhu Y. The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response. Mol Cancer Res 2008; 6: 1461-8.
11. Zhu Y, Stevens RG, Leaderer D et al. Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk. Breast Cancer Res Treat 2008; 107: 421-5.
12. Chu LW, Zhu Y, Yu K et al. Variants in circadian genes and prostate cancer risk: a population-based study in China. Prostate Cancer Prostatic Dis 2008; 11: 342-8.
13. Zhu Y, Leaderer D, Guss C et al. Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma. Int J Cancer 2007; 120: 432-5.
14. Yi C, Mu L, de la Longrais IA et al. The circadian gene NPAS2 is a novel prognostic biomarker for breast cancer. Breast Cancer Res Treat 2009; 120: 663-9.
15. Zhou F, He X, Liu H et al. Functional polymorphisms of circadian positive feedback regulation genes and clinical outcome of Chinese patients with resected colorectal cancer. Cancer 2011; 118: 937-46.
16. Filipski E, Subramanian P, Carriere J, Guettier C, Barbason H, Levi F. Circadian disruption accelerates liver carcinogenesis in mice. Mutat Res 2009; 680(1-2): 95-105.
17. Lin YM, Chang JH, Yeh KT et al. Disturbance of circadian gene expression in hepatocellular carcinoma. Mol Carcinog 2008; 47: 925-33.
18. Oshima T, Takenoshita S, Akaike M et al. Expression of circadian genes correlates with liver metastasis and outcomes in colorectal cancer. Oncol Rep 2011; 25: 1439-46.
19. Zhao B, Lu J, Yin J et al. A functional polymorphism in PER3 gene is associated with prognosis in hepatocellular carcinoma. Liver Int 2012; 32: 1451-9.
20. Bersten DC, Sullivan AE, Peet DJ, Whitelaw ML. bHLH-PAS proteins in cancer. Nat Rev Cancer 2013; 13: 827-41.
21. Shi H, Zhou Y, Liu H et al. Expression of CIAPIN1 in human colorectal cancer and its correlation with prognosis. BMC Cancer 2010; 10: 477.
22. Levi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol 2010; 50: 377-421.
23. Chen-Goodspeed M, Lee CC. Tumor suppression and circadian function. J Biol Rhythms 2007; 22: 291-8.
24. Lee CC. Tumor suppression by the mammalian Period genes. Cancer Causes Control 2006; 17: 525-30.
25. Hua H, Wang Y, Wan C et al. Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer Sci 2006; 97: 589-96.
26. Yi CH, Zheng T, Leaderer D, Hoffman A, Zhu Y. Cancer-related transcriptional targets of the circadian gene NPAS2 identified by genome-wide ChIP-on-chip analysis. Cancer Lett 2009; 284: 149-56.
27. Shi M, Lu LG, Fang WQ et al. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. J Natl Cancer Inst 2013; 105: 59-68.
28. Yuen MF, Chan AO, Wong BC et al. Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients. Am J Gastroenterol 2003; 98: 1181-5.